Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
life sciences
3
×
boston top stories
gilead sciences
national blog main
national top stories
novartis
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
abbvie
allergan aesthetics
alzheimer's disease
amgen
astrazeneca
athira pharma
attralus
biobucks
bioinnovation capital
biolabs
biontech
boehringer ingelheim
boston
boulder/denver blog main
boulder/denver top stories
calistoga pharmaceuticals
cancer
cancer drugs
car-t immunotherapy
checkpoint inhibitors
chemotherapy
chiesi farmaceutici
cholestatic liver diseases
click therapeutics
covid-19
cullinan oncology
cystic fibrosis
daniel o'day
What
drug
3
×
sciences
3
×
gilead
pipeline
acquisitions
adding
bets
biggest
bio
biotech
boost
build
buy
cancer
ceo
company’s
daniel
debut
driving
dyne’s
expensive
far
good
healthcare
history
improved
industry
innovation
innovations
investment
life
long
medical
microbiome
million
moves
openly
outcomes
o’day
paying
Language
unset
Current search:
sciences
×
drug
×
" life sciences "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango
